AEON Biopharma
AEON
30 hedge funds and large institutions have $10.1M invested in AEON Biopharma in 2024 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 7 closing their positions.
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
25% more funds holding
Funds holding: 24 → 30 (+6)
15% more capital invested
Capital invested by funds: $8.73M → $10.1M (+$1.32M)
0% more ownership
Funds ownership: 0.33% → 0.34% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOCH
Blue Owl Capital Holdings
New York
|
+$4.08M |
| 2 |
FAM
Formidable Asset Management
Cincinnati,
Ohio
|
+$338K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$175K |
| 4 |
Two Sigma Investments
New York
|
+$79.7K |
| 5 |
CG
Caprock Group
Boise,
Idaho
|
+$76.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DKCM
Davidson Kempner Capital Management
New York
|
-$94.6K |
| 2 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$91.8K |
| 3 |
Millennium Management
New York
|
-$53.5K |
| 4 |
YIH
Y-Intercept (HK)
Hong Kong
|
-$22K |
| 5 |
KL
KIM LLC
Wichita,
Kansas
|
-$16.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $5.52K | +$176 | +2 | +3% |
|
27
CIBC Private Wealth Group
Atlanta,
Georgia
| $2.54K | +$2.99K | +34 | New |
|
28
Morgan Stanley
New York
| $1.89K | – | – | – |
|
|
GIA
29
GHP Investment Advisors
Denver,
Colorado
| $1.15K | – | – | – |
|
30
JP Morgan Chase
New York
| $61 | +$88 | +1 | New |
|
|
DKCM
31
Davidson Kempner Capital Management
New York
| – | -$94.6K | -1,251 | Closed |
|
|
32
Millennium Management
New York
| – | -$53.5K | -708 | Closed |
|
|
YIH
33
Y-Intercept (HK)
Hong Kong
| – | -$22K | -291 | Closed |
|
|
KL
34
KIM LLC
Wichita,
Kansas
| – | -$16.3K | -216 | Closed |
|
|
CL
35
CSS LLC
Chicago,
Illinois
| – | -$12.7K | -169 | Closed |
|
36
Goldman Sachs
New York
| – | -$11.9K | -157 | Closed |
|
37
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$1.11K | -15 | Closed |
|
AEON Hedge Fund Activity: Q3 2024 in Review
30 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q3 2024, worth a combined $10.1M — up 15% from $8.73M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new AEON positions and 7 closed out — a net gain of 7 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Blue Owl Capital Holdings, opening a new position worth an estimated $4.08M. The largest seller was Davidson Kempner Capital Management, exiting entirely with an estimated $94.6K sold.
- 30 institutional investors held AEON Biopharma (AEON) as of Q3 2024, up from 24 in Q2 2024.
- Funds reported $10.1M of AEON Biopharma stock for Q3 2024, up 15% quarter-over-quarter.
- 14 funds opened new AEON Biopharma positions in Q3 2024 and 7 closed out, a net change of +7 holders.
- The largest AEON Biopharma buyer in Q3 2024 was Blue Owl Capital Holdings, an estimated $4.08M added.
- The largest AEON Biopharma seller in Q3 2024 was Davidson Kempner Capital Management, an estimated $94.6K sold.
Based on aggregated 13F filings for Q3 2024.